Gibel announced the implementation of the semi-annual equity distribution in 2021. The profit distribution is based on 186941600 shares of the company's total share capital before the implementation of the plan, with a cash dividend of 0.24 yuan per share (including tax), resulting in a total cash dividend of 44865984.00 yuan (including tax). Equity registration date October 25, 2021, excluding rights (interest) date October 26, 2021.
Gibel 2021 reported that the company's main income was 251 million yuan, up 3.18% from the same period last year; net profit from home was 55.6496 million yuan, up 22.31% from the same period last year; deducting 47.3682 million yuan from non-net profit, up 5.09% from the same period last year; among them, in the second quarter of 2021, the company's main income in a single quarter was 131 million yuan, up 3.31% from the same period last year; and net profit in a single quarter was 28.6704 million yuan, up 40.56% from the same period last year. The non-net profit in a single quarter was 21.5569 million yuan, up 5.03% from the same period last year; the debt ratio was 8.82%, the investment income was 8.0867 million yuan, the financial expenses were-1.7991 million yuan, and the gross profit margin was 88.29%.
The chairman of the company is Geng Zhongyi. Mr. Geng Zhongyi: born in 1963, Chinese nationality, no permanent residence abroad, bachelor's degree, senior economist, licensed pharmacist, Mr. Geng Zhongyi has worked in Yancheng Pharmaceutical Company, Zhenjiang Pharmaceutical Industry Research Institute, Zhenjiang No. 3 Pharmaceutical Factory, Zhenjiang Yangtze River Sanitary products Factory, Zhenjiang second Pharmaceutical Factory, Zhenjiang Zhongtian Pharmaceutical Co., Ltd., served as technical director, factory director, general manager, chairman and other positions From November 2001 to September 2014, he served as chairman of Jiangsu Jibel Pharmaceutical Co., Ltd., and served as chairman and general manager of the company since September 2014. Mr. Geng Zhongyi personally participated in the research and development of many new drug projects of the company, applied for a number of invention patents related to nitrenolol tablets, antidepressants and other related inventions, and won the first prize of science and technology in Shanghai. it has been awarded as the advanced individual of scientific and technological cooperation in Zhenjiang, the scientific and technological pacesetter of Zhenjiang, the excellent scientific and technological worker in Zhenjiang, the training object of the first batch of "Science and Technology Entrepreneur training Project" in Jiangsu Province, Jiangsu Science and Technology Entrepreneur and other titles. He is also the executive director of China Pharmaceutical quality Management Association, the director of Jiangsu Medical quality Management Association, and the honorary chairman of Zhenjiang Pharmaceutical Association.